阿斯利康以高达 10 亿美元的价格收购了 EsoBiotec，以促进癌症和自身免疫性疾病细胞疗法。 AstraZeneca buys EsoBiotec for up to $1 billion to boost cancer and autoimmune disease cell therapies.

阿斯利康以高达 10 亿美元的价格收购 EsoBiotec，以增强其用于癌症治疗的细胞治疗能力。 AstraZeneca is acquiring EsoBiotec for up to $1 billion to enhance its cell therapy capabilities for cancer treatments. EsoBiotec 的技术可以直接在体内对免疫细胞进行编程，从而有可能将治疗时间从数周缩短到几分钟。 EsoBiotec's technology can program immune cells directly in the body, potentially reducing treatment time from weeks to minutes. 该交易包括 4.25 亿美元的预付款和高达 5.75 亿美元的里程碑付款。 The deal includes a $425 million upfront payment and up to $575 million in milestone payments. 此次收购是阿斯利康加强其在肿瘤学和细胞治疗领域地位的战略的一部分。 This acquisition is part of AstraZeneca's strategy to strengthen its position in oncology and cell therapy.